Valeo Pharma Announces Listing of its Shares on the Canadian Securities Exchange Under the Symbol VPH

MONTREAL, Feb. 20, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo Pharma") a Canadian specialty pharmaceutical company, is pleased to announce the listing and trading of its shares on the Canadian Securities Exchange ("CSE") under the symbol "VPH". Founded in 2003, Valeo Pharma has a long history of succesfully commercializing pharmaceutical products in Canada and is therapeutically focused on neurodegenerative diseases, woman's health and oncology. With the recent approval by Health Canada of Onstryv, a novel treatment for Parkinson's disease, Valeo Pharma is preparing for the launch of five products in 2019.

 "This is an exciting time for Valeo Pharma's shareholders, employees and pharmaceutical partners," said Steve Saviuk, Chief Executive Officer of Valeo Pharma. "Following the sale of our dermatology portfolio in 2014 our team has worked extensively on developing the company's new therapeutic areas of focus. The approval by Health Canada of Onstryv for the treatment of Parkinson's disease is a significant milestone for our company. Valeo Pharma is now  preparing for Onstryv's commercial launch in the second quarter of calendar 2019. We are also making preparations  for the launch of our first prescription product in women's health and three other products in our growing hospital specialty portfolio, including our first product entry into the U.S.. Our product pipeline continues to expand reflecting our experienced and diverse regulatory and commercial capabilities. With our upcoming product launches and revenue growth, Valeo Pharma is well positioned for a successful debut on the CSE as a publicly traded specialty pharma company."

About Valeo Pharma

Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada. With a focus on neurodegenerative diseases, woman's health and oncology, Valeo Pharma has a growing portfolio of innovative products and the proper infrastructure to manage these products through all stages of commercialization. Headquartered in Kirkland, Quebec, Valeo Pharma has all the internal capabilities to register and market health care solutions for Canadian patients. For more information, please visit www.valeopharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

SOURCE Valeo Pharma inc.

For further information: Steve Saviuk - President and CEO, [phone], [e-mail]; Luc Mainville, Sr Vice-President and CFO, [phone], [e-mail]

Related Links

http://www.valeopharma.com